Table 2.
Sociodemographic characteristics of the original psymetric development sample and included external validation samples.
| Characteristic | Original PsyMetRiC Development Sample (UK) | PsyMetab External Validation Sample (Switzerland) | PAFIP External Validation Sample (Spain) | Between-Group Differencesd |
|---|---|---|---|---|
| Sample before Inclusion/Exclusion Criteria Applieda, N. | 1504 | 2852 | 885 | - |
| Included sample sizea, N. (%) | 651 (43.28) | 558 (19.57) | 466 (52.66) | - |
| Age in Years, mean (SD) | 24.52 (4.91) | 25·92 (5.32) | 25·51 (4.99) | F=12.22, p<0.0001 |
| White European/NR Ethnicity, N. (%) | 360 (55.3) | 446 (79.93) | 435 (93.34) | χ=219.67, p<0.0001 |
| Black/African-Caribbean Ethnicity, N. (%) | 109 (16.74) | 68 (12.19) | 15 (3.22) | χ=49.38, p<0.0001 |
| Asian/Other Ethnicity, N. (%) | 181 (27.80) | 44 (7.48) | 16 (3.43) | χ=159.67, p<0.0001 |
| Male Sex, N. (%) | 440 (67.59) | 345 (61.83) | 303 (65.16) | χ=4.38, p=0.112 |
| HDL at baseline, mmol/L, mean (SD) | 1.88 (0.57) | 1.33 (0.36) | 1.32 (0.34) | F=303.57, p<0.0001 |
| Triglycerides at baseline, mmol/L, mean (SD) | 1.39 (1.06) | 1.16 (0.70) | 0.88 (0.40) | F=54.89, p<0.0001 |
| BMI at baseline, kg/m2, mean (SD) | 23.63 (5.43) | 23.60 (5.00) | 22.50 (3.36) | F=9.14, p<0.0001 |
| FPG at baseline (mmol/L), mean (SD) | 5.19 (1.28) | 4.95 (0.82) | 4.69 (0.55) | F=36.11, p<0.0001 |
| Systolic BP at baseline (mmHg), mean (SD) | 120.65 (11.68) | 121.32 (14.00) | 119.86 (14.10) | F=1.56, p=0.211 |
| Prescribed a More-Metabolically-Active Antipsychoticb, N. (%) | 455 (69.89) | 413 (74.01) | 234 (50.21) | χ=71.87, p<0.0001 |
| Smoking at baseline, N. (%) | 315 (48.39) | 362 (64.87) | 279 (59.90) | χ=35.40, p<0.0001 |
| Follow-up time, years, mean (SD) | 1.86 (1.32) | 2.48 (1.40) | 2.59 (0.73) | F=61.47, p<0.0001 |
| Antipsychotic Naïve at baseline, N. (%) | NR | 361 (64.70) | 433 (92.92) | χ=114.53, p<0.0001 |
| Metabolic Syndrome at baseline, N. (%)c | 49 (6.58) | 36 (6.06) | 31 (6.24) | χ=0.53, p=0.766 |
| Metabolic Syndrome at Follow-up, N. (%) | 109 (16.74) | 103 (18.54) | 66 (14.16) | χ=3.40, p=0.183 |
HDL=high-density lipoprotein; BMI=body mass index; FPG=fasting plasma glucose; BP=blood pressure; NR=Not recorded; d.f.=degrees of freedom.
a
See Supplementary Figure 1 for a flow-chart of included participants in the study.
b
Definitions of Metabolically-active antipsychotics are listed in Supplementary Table 1.
c
Corresponds to percentage of sample before those participants were excluded.
d
Analysis of means was conducted using one-way ANOVA. Analysis of proportions was conducted using the chi-square equality of proportions test.